Crescent BiopharmavsJohnson & Johnson

CBIO and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CBIO

Crescent Biopharma, Inc.

$13.00

Value $506M

+0.70%
CBIO's page

Crescent Biopharma (CBIO) has a market value of $506M and Johnson & Johnson (JNJ) $652B. Over the last year, with dividends, CBIO moved -0.2% and JNJ +36.6%. Dividend yield: CBIO none, JNJ 1.95%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CBIO$506M

    JNJ$652B

    JNJ is 1,289 times CBIO

  • Revenue, 12 months

    CBIO$15M

    JNJ$99.3B

    JNJ is 6,622 times CBIO

  • Net income, 12 months

    CBIO-$109M

    JNJ$16.1B

  • Operating margin

    CBIO-1,216.6%

    JNJ–

  • ROIC

    CBIO-76.6%

    JNJ12.4%

    89.0 points apart

  • P/E

    CBIO–

    JNJ40.5

  • Dividend yield

    CBIO0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    CBIO-75.9%

    JNJ+90.9%

    166.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CBIO-75.9%

JNJ+90.9%

020040060020222023202420252026
Returns by period
PeriodCBIOWith dividendsJNJWith dividends
1 year since November 19, 2025-0.2%Price -0.2%+36.6%Price +33.6%
3 years since November 20, 2023-91.5%-56.0% a yearPrice -91.5%+94.9%+24.9% a yearPrice +80.4%
5 years since November 19, 2021-75.9%-24.7% a yearPrice -93.1%+90.9%+13.8% a yearPrice +66.0%
10 years since November 21, 2016-93.2%-23.6% a yearPrice -98.1%+206.5%+11.9% a yearPrice +135.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CBIOCrescent BiopharmaJNJJohnson & Johnson

Valuation

CBIOJNJ
Valuation
Price$13.00$270.47
Market value$506M$652B
Enterprise value (EV)$216M$679B
P/E–40.5
P/E, 5-year median–21.9
P/B1.98.0
EV/EBIT–38.3
Free cash flow yield–3.2%

Results and growth

CBIOJNJ
Results and growth
Revenue, 12 months$15M$99.3B
Net income, 12 months-$109M$16.1B
Free cash flow, 12 months-$82M$20.6B
Earnings per share, 12 months-$3.96$6.59
Revenue growth, year on year3,193.0%6.1%
Revenue growth a year, past+1.3%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

CBIOJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin-1,216.6%–
Net margin-727.6%16.2%
ROIC-76.6%12.4%
ROE-58.0%19.7%

Balance sheet

CBIOJNJ
Balance sheet
Cash$289M$17.2B
Total debt$2.5M$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

CBIOJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CBIO or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Crescent Biopharma or Johnson & Johnson?

By market value, Johnson & Johnson ($652B) is about 1,289.1 times Crescent Biopharma ($506M), at today's prices.

How did CBIO and JNJ stock do over the last 10 years?

Since November 21, 2016, CBIO's price moved -98.1% and JNJ's +135.2%. With dividends: CBIO -93.2% (-23.6% a year), JNJ +206.5% (+11.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, CBIO or JNJ?

The dividend yield at today's price is none for Crescent Biopharma and 1.95% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, Crescent Biopharma or Johnson & Johnson?

Over the last twelve months, the net margin was -727.6% for Crescent Biopharma and 16.2% for Johnson & Johnson, and the operating margin -1,216.6% and –. Revenue was $15M and $99.3B.

Which is the better investment, Crescent Biopharma or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.